

## PATIENT INFORMATION

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Phone: \_\_\_\_\_ Sex: M F Ht: \_\_\_\_\_ Wt: \_\_\_\_\_ lbs kg

Primary Language: \_\_\_\_\_ Allergies: \_\_\_\_\_

Patient Preferred Location: \_\_\_\_\_

<ICD 10 CODE REQUIRED>

## DIAGNOSIS & CLINICAL INFORMATION

### ICD 10 Code

L40.0 Psoriasis Vulgaris  
L40.1 Generalized Pustular Psoriasis  
L40.2 Acrodermatitis Continua  
L40.3 Pustulosis Palmaris et Plantaris  
L40.4 Guttate Psoriasis  
L40.8 Flexural Psoriasis  
L40.9 Psoriasis, Unspecified

Other: \_\_\_\_\_

### Lab Orders+

Required: Negative TB, annually

**+Medix Infusion will draw required maintenance labs unless otherwise directed by Referring Provider**

**REQUIRED:** Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy.

**LAB RESULTS:** Include Negative TB within 12 months.

## PRESCRIPTION

### ILUMYA (tildrakizumab-asmn)

#### Loading Dose

SubQ: Inject 100 mg at weeks 0 and 4

#### Maintenance Dose

SubQ: Inject 100 mg every 12 weeks for one year

Is the patient on any other disease modifying therapy? Yes No

If yes, please note therapy and last dose: \_\_\_\_\_

**Post Treatment Observations:** The patient is observed for 30 minutes following the first administration.

**Adverse Events:** In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol.

#### Comments:

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

## PRESCRIBER INFORMATION

Prescriber Name: \_\_\_\_\_ Signature: \_\_\_\_\_

Date: \_\_\_\_\_ NPI #: \_\_\_\_\_ Specialty: \_\_\_\_\_

Supervising Physician: \_\_\_\_\_ (If Applicable)

Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Contact Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Email: \_\_\_\_\_